Chemistry:Brepocitinib

From HandWiki

Brepocitinib (PF-06700841) is a drug which acts as a dual inhibitor of JAK1 and TYK2, and was developed for the treatment of plaque psoriasis.[1][2][3][4]

See also

References

  1. ↑ "Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)". Journal of Medicinal Chemistry 61 (19): 8597–8612. October 2018. doi:10.1021/acs.jmedchem.8b00917. PMID 30113844. 
  2. ↑ "TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial". The Journal of Investigative Dermatology 140 (12): 2359–2370.e5. December 2020. doi:10.1016/j.jid.2020.03.962. PMID 32311398. 
  3. ↑ "Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors". Dermatology and Therapy 13 (2): 417–435. February 2023. doi:10.1007/s13555-022-00878-9. PMID 36592300. 
  4. ↑ "Recent developments for new investigational JAK inhibitors in psoriatic arthritis". Expert Opinion on Investigational Drugs 32 (5): 361–371. May 2023. doi:10.1080/13543784.2023.2207737. PMID 37096862. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Brepocitinib&oldid=4030774"